Blood Cancer Drugs Global Market Report 2025

Description

Blood cancer drugs are pharmaceutical treatments employed to combat blood cancer by harnessing the body's immune system to slow down the proliferation of cancer cells. These treatments encompass a range of modalities, including chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant, all tailored to address blood cancer effectively.

The primary categories of blood cancer drugs target leukemia and lymphoma. Leukemia pertains to a form of cancer affecting blood-forming tissues, particularly the bone marrow and lymphatic system. Various drug formulations are used in this context, including rituximab (Rituaxan/Mabthera), imatinib (Gleevec/Glivec), lenalidomide (Revlimid), bortezomib (Velcade), nilotinib (Tasigna), pomalidomide (Pomalyst), azacitidine (Fidanza), carfilzomib (Kyphosis), brentuximabvedotin (Adcetris), among others. These drugs are administered through diverse treatment approaches, spanning key findings, chemotherapeutic methods, monoclonal antibodies/targeted therapies, and immunotherapeutic interventions.

The blood cancer drugs market research report is one of a series of new reports from The Business Research Company that provides blood cancer drugs market statistics, including blood cancer drugs industry global market size, regional shares, competitors with a blood cancer drugs market share, detailed blood cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the blood cancer drugs industry. This blood cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The blood cancer drugs market size has grown strongly in recent years. It will grow from $74.78 billion in 2024 to $80.79 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to advancements in research and development, aging population, increased awareness and early diagnosis, regulatory approvals.

The blood cancer drugs market size is expected to see strong growth in the next few years. It will grow to $106.8 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing disease prevalence, emerging markets, supportive care. Major trends in the forecast period include research and development investments, combination therapies, biomarker identification, immunotherapy advancements, personalized medicine.

The blood cancer drugs market is experiencing growth due to the escalating number of deaths and the rising prevalence of blood cancer cases worldwide. Various forms of blood cancers, including lymphoma, leukemia, myeloma, and others, have distinct risk factors. Some can be managed or prevented through drug therapies, while others may result in fatalities. According to a report by Bristol-Myers Squibb Company, it is projected that by 2040, over 1.85 million new blood cancer cases will be diagnosed globally. These cases will include 918,872 instances of lymphoma, 656,345 of leukemia, and 275,047 of myeloma. The report further estimates that by 2040, around 1,100,000 deaths will occur worldwide due to blood cancer. The increasing number of deaths and the surging incidence of blood cancer cases are propelling the growth of the blood cancer drug market.

Major companies operating in the blood cancer drugs market are focusing on developing new drugs and seeking FDA approval to gain a competitive edge. FDA approval refers to the formal authorization granted by the United States Food and Drug Administration (FDA) for a pharmaceutical product to be legally marketed and sold in the U.S. For example, in March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, received FDA approval for its first and only CAR T-cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This accelerated approval allows its use in patients who have previously received at least two treatments, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor. Based on the TRANSCEND CLL 004 trial, Breyanzi showed a 20% complete response rate and a median duration of response of 35.3 months among responders.

Major players in the blood cancer drugs market are actively engaged in the development of novel drugs and pursuing FDA approval to gain a competitive edge in the industry. FDA approval for drugs is the formal authorization issued by the United States Food and Drug Administration (FDA) for the legal marketing and sale of a pharmaceutical product in the United States. These approvals hold immense value in the market. In May 2023, the FDA granted its approval to Epcoritamab, commercially known as Epkinly, for the treatment of diffuse large B-cell lymphoma (DLBCL) in patients who have undergone at least two prior lines of systemic therapy. Epkinly, classified as a CD20xCD3 T-cell engager, exhibited significant efficacy during clinical trials, with a 61% tumor shrinkage rate in patients who had previously received multiple treatments. This approval serves as a noteworthy addition to the available treatment options for DLBCL.

In July 2022, GSK, a prominent pharmaceutical company based in the UK, completed the acquisition of Sierra Oncology for an undisclosed sum. This strategic acquisition bolsters GSK's oncology portfolio. Sierra Oncology, headquartered in the United States, specializes in the development of cancer drugs, including treatments for blood cancers.

Major companies operating in the blood cancer drugs market include Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Roche Holding AG, Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Regeneron Pharmaceuticals Inc., Seattle Genetics Inc., Servier Laboratories, Shire PLC, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A., Vertex Pharmaceuticals Incorporated

North America was the largest region in the blood cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the blood cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The blood cancer drugs market consists of sales Altretamine, Bendamustine, Bendamustine, and Carboplatin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Blood Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on blood cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for blood cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The blood cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Blood Cancer Type: Leukemia; Lymphoma
2) By Drugs: Rituxan Or Mabthera (Rituximab); Gleevec Or Glivec (Imatinib); Revlimid (Lenalidomide); Velcade (Bortezomib); Tasigna (Nilotinib); Pomalyst (Pomalidomide); Vidaza (Azacitidine); Kyprolis (Carfilzomib); Adcetris (Brentuximab Vedotin); Other Drugs
3) By Treatment Approaches: Key Findings; Chemotherapeutic; MAbs/Targeted Therapies; Immunotherapeutic
Subsegments:
1) By Leukemia: Acute Lymphoblastic Leukemia (ALL); Chronic Lymphocytic Leukemia (CLL); Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML); Other Types of Leukemia
2) By Lymphoma: Hodgkin Lymphoma; Non-Hodgkin Lymphoma (NHL); Burkitt Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Other Types of Lymphoma
Companies Mentioned: Amgen Inc.; AstraZeneca PLC; Bayer AG; Eli Lilly and Company Inc.; Johnson & Johnson
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r32421

1. Executive Summary

2. Blood Cancer Drugs Market Characteristics

3. Blood Cancer Drugs Market Trends And Strategies

4. Blood Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Blood Cancer Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Blood Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Blood Cancer Drugs Market Growth Rate Analysis
5.4. Global Blood Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Blood Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Blood Cancer Drugs Total Addressable Market (TAM)

6. Blood Cancer Drugs Market Segmentation

6.1. Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Leukemia
Lymphoma
6.2. Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rituxan Or Mabthera (Rituximab)
Gleevec Or Glivec (Imatinib)
Revlimid (Lenalidomide)
Velcade (Bortezomib)
Tasigna (Nilotinib)
Pomalyst (Pomalidomide)
Vidaza (Azacitidine)
Kyprolis (Carfilzomib)
Adcetris (Brentuximab Vedotin)
Other Drugs
6.3. Global Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Key Findings
Chemotherapeutic
MAbs/Targeted Therapies
Immunotherapeutic
6.4. Global Blood Cancer Drugs Market, Sub-Segmentation Of Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Lymphoblastic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Acute Myeloid Leukemia (AML)
Chronic Myeloid Leukemia (CML)
Other Types of Leukemia
6.5. Global Blood Cancer Drugs Market, Sub-Segmentation Of By Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hodgkin Lymphoma
Non-Hodgkin Lymphoma (NHL)
Burkitt Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Other Types of Lymphoma

7. Blood Cancer Drugs Market Regional And Country Analysis

7.1. Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Blood Cancer Drugs Market

8.1. Asia-Pacific Blood Cancer Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Blood Cancer Drugs Market

9.1. China Blood Cancer Drugs Market Overview
9.2. China Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Blood Cancer Drugs Market

10.1. India Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Blood Cancer Drugs Market

11.1. Japan Blood Cancer Drugs Market Overview
11.2. Japan Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Blood Cancer Drugs Market

12.1. Australia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Blood Cancer Drugs Market

13.1. Indonesia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Blood Cancer Drugs Market

14.1. South Korea Blood Cancer Drugs Market Overview
14.2. South Korea Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Blood Cancer Drugs Market

15.1. Western Europe Blood Cancer Drugs Market Overview
15.2. Western Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Blood Cancer Drugs Market

16.1. UK Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Blood Cancer Drugs Market

17.1. Germany Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Blood Cancer Drugs Market

18.1. France Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Blood Cancer Drugs Market

19.1. Italy Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Blood Cancer Drugs Market

20.1. Spain Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Blood Cancer Drugs Market

21.1. Eastern Europe Blood Cancer Drugs Market Overview
21.2. Eastern Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Blood Cancer Drugs Market

22.1. Russia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Blood Cancer Drugs Market

23.1. North America Blood Cancer Drugs Market Overview
23.2. North America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Blood Cancer Drugs Market

24.1. USA Blood Cancer Drugs Market Overview
24.2. USA Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Blood Cancer Drugs Market

25.1. Canada Blood Cancer Drugs Market Overview
25.2. Canada Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Blood Cancer Drugs Market

26.1. South America Blood Cancer Drugs Market Overview
26.2. South America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Blood Cancer Drugs Market

27.1. Brazil Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Blood Cancer Drugs Market

28.1. Middle East Blood Cancer Drugs Market Overview
28.2. Middle East Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Blood Cancer Drugs Market

29.1. Africa Blood Cancer Drugs Market Overview
29.2. Africa Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Blood Cancer Drugs Market Competitive Landscape And Company Profiles

30.1. Blood Cancer Drugs Market Competitive Landscape
30.2. Blood Cancer Drugs Market Company Profiles
- 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Eli Lilly and Company Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

31. Blood Cancer Drugs Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Pfizer Inc.
31.3. AbbVie Inc.
31.4. Takeda Pharmaceutical Company Limited
31.5. F. Hoffmann-La Roche Ltd.
31.6. Bristol-Myers Squibb Company
31.7. Astellas Pharma Inc.
31.8. Roche Holding AG
31.9. Merck & Co. Inc.
31.10. Gilead Sciences Inc.
31.11. Sanofi S.A.
31.12. Eisai Co. Ltd.
31.13. Jazz Pharmaceuticals plc
31.14. Kyowa Kirin Co. Ltd.
31.15. Menarini Group

32. Global Blood Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Blood Cancer Drugs Market

34. Recent Developments In The Blood Cancer Drugs Market

35. Blood Cancer Drugs Market High Potential Countries, Segments and Strategies

35.1 Blood Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Blood Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Blood Cancer Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer